Diclofenac for Prevention of Post-ERC Pancreatitis

Summary

The study aims at assessing the effectiveness of Diclofenac for prevention of post-ERCP pancreatitis. It will be undertaken embedded in the Swedish national register for Gallstone surgery and ERCP (GallRiks). Patients are randomised to Diclofenac prior to the ERCP or no prophylaxis. GallRiks is used to identify which patients fulfill the eligibility criteria and which patients develop pancreatitis after the ERCP.

Timeline

Start

2026-01-01

Primary completion

2027-12-31

Completion

2028-12-31

Drugs

Indications